Filter by Category: Medical Writing

Cefepime-Enmetazobactam (formerly AAI101; 30/20 µg) and Cefepime (30 µg) Disk Diffusion Quality Control Ranges Using a CLSI M23 (2018) Multi-Laboratory Study Design

Cefepime-Enmetazobactam (formerly AAI101; 30/20 µg) and Cefepime (30 µg) Disk Diffusion Quality Control Ranges Using a CLSI M23 (2018) Multi-Laboratory Study Design. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2778

Correlation between Broth Microdilution and Disk Diffusion Methods Results when Testing Ceftaroline against Methicillin-Resistant Staphylococcus aureus Using the 5-µg Ceftaroline Disk

Correlation between Broth Microdilution and Disk Diffusion Methods Results when Testing Ceftaroline against Methicillin-Resistant Staphylococcus aureus Using the 5-µg Ceftaroline Disk. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2783

Synergistic Activity of Colistin and Zidovudine (AZT) Combinations against Colistin-Resistant Enterobacteriaceae

Synergistic Activity of Colistin and Zidovudine (AZT) Combinations against Colistin-Resistant Enterobacteriaceae. Lead author: LR Duncan, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2787

Spectrum of Activity of RX-P2382, a Novel Class of Bacterial Ribosome Inhibitor.

Spectrum of Activity of RX-P2382, a Novel Class of Bacterial Ribosome Inhibitor. Lead author: D Shortridge, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#46

Antimicrobial Activity Assessment of Tebipenem (SPR859) against an Isolate Collection Causing Urinary Tract Infections

Antimicrobial Activity Assessment of Tebipenem (SPR859) against an Isolate Collection Causing Urinary Tract Infections. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-560

Antimicrobial Activity of GT-1, a Novel Siderophore Cephalosprin, Tested against Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter spp. Isolates

Antimicrobial Activity of GT-1, a Novel Siderophore Cephalosprin, Tested against Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter spp. Isolates. Lead author: LR Duncan, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-577

A systematic approach to the selection of the appropriate avibactam concentration for use with ceftazidime in broth microdilution susceptibility testing.

A systematic approach to the selection of the appropriate avibactam concentration for use with ceftazidime in broth microdilution susceptibility testing. by Bradford PA, Huband MD and Stone GG published in Antimicrob. Agents Chemother.: in press, 2018.

Disk content assessment and proposed breakpoint interpretive criteria for cefepime in combination with AAI101.

Disk content assessment and proposed breakpoint interpretive criteria for cefepime in combination with AAI101. Lead author: MD Huband, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
#P0157

Assessment of ceftazidime-avibactam 30/20 µg disk content versus MIC results when tested against Enterobacteriaceae and Pseudomonas aeruginosa.

Assessment of ceftazidime-avibactam 30/20 µg disk content versus MIC results when tested against Enterobacteriaceae and Pseudomonas aeruginosa. by Sader HS, Rhomberg PR, Huband MD, Critchley IA, Stone GG, Flamm RK and Jones RN published in J. Clin. Microbiol. 2018 in press

Dilution factor of quantitative bacterial cultures obtained by bronchoalveolar lavage in patients with ventilator-associated bacterial pneumonia: Implications for optimal antimicrobial therapy ventilator-associated bacterial pneumonia study group.

Dilution factor of quantitative bacterial cultures obtained by bronchoalveolar lavage in patients with ventilator-associated bacterial pneumonia: Implications for optimal antimicrobial therapy ventilator-associated bacterial pneumonia study group. by Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo Torre CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M and Berman C published in Antimicrob. Agents Chemother. 2018; in press